Treatment of microvascular angina: the need for precision medicine

Affiliations

¹ Istituto di Cardiologia, Università Cattolica del Sacro Cuore, Rome Italy filippo.crea@rm.unicatt.it.
² Istituto di Cardiologia, Università Cattolica del Sacro Cuore, Rome Italy.

Editorial

Filippo Crea et al. Eur Heart J. 2016.

. 2016 May 14;37(19):1514-6.

doi: 10.1093/eurheartj/ehw021. Epub 2016 Feb 18.

¹ Istituto di Cardiologia, Università Cattolica del Sacro Cuore, Rome Italy filippo.crea@rm.unicatt.it.
² Istituto di Cardiologia, Università Cattolica del Sacro Cuore, Rome Italy.

No abstract available

Comment on

A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve.
Bairey Merz CN, Handberg EM, Shufelt CL, Mehta PK, Minissian MB, Wei J, Thomson LE, Berman DS, Shaw LJ, Petersen JW, Brown GH, Anderson RD, Shuster JJ, Cook-Wiens G, Rogatko A, Pepine CJ. Bairey Merz CN, et al. Eur Heart J. 2016 May 14;37(19):1504-13. doi: 10.1093/eurheartj/ehv647. Epub 2015 Nov 27. Eur Heart J. 2016. PMID: 26614823 Free PMC article. Clinical Trial.